Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 29, 2004Hypertension

Coadministration of lower doses of olmesartan (0.5 mg/kg per day) and azelnidipine (0.1 mg/kg per day) significantly inhibited vascular remodeling parameters, and azelnidipine (1 mg/kg per day) exaggerated the inhibitory action of olmesartan (1 or 3 mg/kg per day) on VSMC proliferation.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does azelnidipine enhance the vascular protective effects of olmesartan in a mouse model of vascular injury?

Population

Wild-type and AT1a receptor null mice with polyethylene cuff-induced vascular injury of the femoral artery

Comparison

Azelnidipine alone, or coadministration of… vs Untreated or vehicle-treated injured mice

Design

Preclinical

Authors

TJToyohisa JinnoMIMasaru IwaiZLZhen Li

Discussion

Loading...

Member takes

Overview

May support ARB-CCB synergy in preclinical vascular models; leaves open translation to human disease.

Structured PICO

Does azelnidipine enhance the vascular protective effects of olmesartan in a mouse model of vascular injury?

P
Population
Wild-type and AT1a receptor null mice with polyethylene cuff-induced vascular injury of the femoral artery
I
Intervention
Azelnidipine (0.5 or 1 mg/kg per day) alone, or coadministration of olmesartan (0.5, 1, or 3 mg/kg per day) and azelnidipine (0.1 or 1 mg/kg per day)
C
Comparator
Untreated or vehicle-treated injured mice (implied)
O
Outcome
Vascular remodeling parameters including VSMC proliferation, neointimal formation, ERK activation, STAT1/3 phosphorylation, inflammatory response, and oxidative stresssurrogate

Azelnidipine enhances the vascular protective effects of olmesartan against vascular injury in a mouse model, suggesting potential clinical benefits of combining CCBs and ARBs for vascular diseases.

Cite This Study

Jinno et al. (2004) studied this question.

synapsesocial.com/papers/6a70e38875498292b70a5fc5https://doi.org/10.1161/01.hyp.0000113627.08110.6f
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prevention of Vascular Injury by Combination of an AT1 Receptor Blocker, Olmesartan, With Various Calcium Antagonists2008 · 25 citations
  2. 2The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage2006 · 21 citations
  3. 3Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice2005 · 47 citations
  4. 4Calcium Channel Blockers, More than Diuretics, Enhance Vascular Protective Effects of Angiotensin Receptor Blockers in Salt-Loaded Hypertensive Rats2012 · 8 citations
  5. 5Comparative Effects of Olmesartan and Azelnidipine on Atrial Structural Remodeling in Spontaneously Hypertensive Rats2009 · 7 citations